| Project/Area Number |
14570166
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
YASUDA Masanori Tokai University, School of Medicine, Assistant Professor, 医学部, 講師 (50242508)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MURAMATSU Toshinari Tokai University, School of Medicine, Assistant Researcher, 医学部, 助手 (90266437)
OSAMURA Yoshiyuki Tokai University, School of Medicine, Professor, 医学部, 教授 (10100992)
TAKEKOSHI Susumu Tokai University, School of Medicine, Assistant Professor, 医学部, 講師 (70216878)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 2003: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2002: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | endometrial adenocarcinoma / carbohydrate antigen / DU-PAN-2 / CA19-9 / 体癌 / 1型糖鎖 / 腫瘍マーカー |
|---|
| Research Abstract |
Serum elevations of carbohydrate antigens ; DU-PAN-2 and CA19-9 in endometrial adenocarcinomas (EACs) were characterized, particularly focusing on clarification of DU-PAN-2 expression profiles. Sixty-four resected EACs of endometrioid type were used. The preoperative serum values of the markers were measured and comparatively analyzed regarding the relationship between histological grade and clinicopathological stage. The overall ratios of positive cases were 26.2% for DU-PAN-2 and 25.0% for CA19-9. DU-PAN-2 decreased as the grading went up, however the reverse was true with CA19-9. During staging-up from I+II to III+IV, the positive ratios inclined as follows : DU-PAN-2, 18.4% to 53.3% ; CA19-9, 20.4% to 40.0%. It is suggested that DU-PAN-2 tends to be produced more in well-differentiated components of EACs than in poorly-differentiated ones. Since approximately half the cases with BAGs were serologically positive for DU-PAN-2 in stage III+IV, the marker is believed to be one of much use for monitoring the cases with an extrauterine extent.
|
